obe drug

HideShow resource information
  • Created by: hadar
  • Created on: 23-11-15 09:35
Metformin- mechanism of action
activation by metformin of AMP-activated protein kinase (AMPK), AMPK is known to cause GLUT4 deployment to the plasma membrane, resulting in insulin-independent glucose uptake.
1 of 8
Metformin- therapeutic affect
decreases blood glucose levels by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization.
2 of 8
Gliclazide- mechanism of action
binds β cell sulfonyl urea receptor (SUR1).blocks ATP sensitive potassium channels.decrease potassium efflux--> depolarization β cells.opens voltage-dependent calcium channels in β cell resulting calmodulin activation,exocytosis of insulin
3 of 8
Gliclazide- therapeutic affect
stimulates β cells of the islet of Langerhans in the pancreas to release insulin. enhances peripheral insulin sensitivity.potentiates insulin release and improves insulin dynamics.
4 of 8
Insulin- mechanism of action
inhibits gluconeogenesis in the liver. binds to the insulin receptorbinding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor.
5 of 8
Insulin- therapeutic affect
By insulin binding to the receptors is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1.lead to the activation of downstream signaling molecules
6 of 8
Orlistat- mechanism of action
reversible inhibitor of lipases, inhibiting gastric and pancreatic lipases
7 of 8
Orlistat- therapeutic affect
lipase activity is blocked, triglycerides from the diet are not hydrolyzed into absorbable free fatty acids, and instead are excreted unchanged.
8 of 8

Other cards in this set

Card 2

Front

decreases blood glucose levels by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization.

Back

Metformin- therapeutic affect

Card 3

Front

binds β cell sulfonyl urea receptor (SUR1).blocks ATP sensitive potassium channels.decrease potassium efflux--> depolarization β cells.opens voltage-dependent calcium channels in β cell resulting calmodulin activation,exocytosis of insulin

Back

Preview of the back of card 3

Card 4

Front

stimulates β cells of the islet of Langerhans in the pancreas to release insulin. enhances peripheral insulin sensitivity.potentiates insulin release and improves insulin dynamics.

Back

Preview of the back of card 4

Card 5

Front

inhibits gluconeogenesis in the liver. binds to the insulin receptorbinding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor.

Back

Preview of the back of card 5
View more cards

Comments

No comments have yet been made

Similar Other resources:

See all Other resources »See all pharm resources »